The effect of visfatin rs2110385 gene polymorphism over
oral antidiabetic drug response

Koldemir Gunduz, Meliha; ÇAGATAY, PENBE; SUSLEYICI, Belgin; KAYHAN, Figen Esin; TASKIN, MUSTAFA

doi:10.5455/annalsmedres.2021.02.129

The effect of visfatin rs2110385 gene polymorphism over oral antidiabetic drug response

Belgin SUSLEYİCİ, (Marmara Üniversitesi, Fen-Edebiyat Fakültesi, Biyoloji Anabilim Dalı, Moleküler Biyoloji Bölümü, İstanbul, Türkiye)

MELİHA KOLDEMİR GÜNDÜZ, (Kütahya Sağlık Bilimleri Üniversitesi, Mühendislik ve Doğa Bilimleri Fakültesi, Mühendislik Temel Bilimler Bölümü, Kütahya, Türkiye)

Figen Esin KAYHAN, (Marmara Üniversitesi, Fen-Edebiyat Fakültesi, Biyoloji Anabilim Dalı, Zooloji Bölümü, İstanbul, Türkiye)

Penbe ÇAĞATAY, (Balıkesir Üniversitesi, Tıp Fakültesi, Biyoistatistik ve Tıbbi Bilgi Anabilim Dalı, Balıkesir, Türkiye)

Mustafa TASKİN (İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, Genel Cerrahi Anabilim Dalı, İstanbul, Türkiye)

Annals of Medical Research

1 2

Yıl: 2021 Cilt: 28 Sayı: 12 Sayfa Aralığı: 2134 - 2139 Metin Dili: İngilizce DOI: 10.5455/annalsmedres.2021.02.129 İndeks Tarihi: 06-06-2022

The effect of visfatin rs2110385 gene polymorphism over oral antidiabetic drug response

Öz:

Aim: The aim of our study is to investigate the effects of rs2110385 polymorphism of the visfatin gene on obesity in Turkish study groups. The rs2110385 polymorphism was analyzed in terms of genotype frequencies, obesity-related parameters, demographic data, serum visfat-in levels and drug use in obese and non-obese subjects. Materials and Methods: The PCR-RFLP method was used to determine the visfatin gene rs2110385 genotype. MicroELISA method was used to measure serum visfatin levels. Results: Homozygous wild type (G / G), heterozygous (G / T) and homozygous polymor-phic (T / T) genotype frequencies of the visfatin gene rs2110385 polymorphism was found to be respectively as, 54.1%, 66.7%, 61.8% in obese and 45.9%, 33.3%, 38.2% in non-obese. There was no statistical difference between the groups in terms of genotype frequen-cies and serum visfatin levels. Homozygous wild type genotype frequency was higher than heterozygous and homozygous polymorphic genotype in obese group with type 2 diabetes mellitus using sulfonylurea and glinide, respectively. The rs2110385 mutation reduced the response to antidiabetics in obese patients with type 2 diabetes mellitus. Conclusions: In conclusion, our results may indicate that obese type 2 diabetic patients with the visfatin gene T / T rs2110385 genotype may benefit more efficiently from oral an-tidiabetic drugs other than glinide or sulfonylurea.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Gulcelik NE, Usman A, Gurlek A. Role of adipocytokines in predicting the devel-opment of diabetes and its late complications. Endocrine 2009;36:397-403.
2. Okamoto Y, Kihara S, Funahashi T, et al. Adiponectin: a key adipocytokine in meta-bolic syndrome. Clin Sci (Lond) 2006;110: 267-78.
3. Berndt J, Klöting N, Kralisch S, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005;54:2911-6.
4. Chen CC, Li TC, Li CI, et al. The relationship between visfatin levels and anthro-pometric and metabolic parameters: association with cholesterol levels in women. Metabolism 2007;56:1216-20.
5. Filippatos TD, Derdemezis CS, Gazi IF, et al. Increased plasma visfatin levels in subjects with the metabolic syndrome. Eur J Clin Invest 2008;38:71-2.
6. Araki S, Dobashi K, Kubo K, et al. Plasma visfatin concentration as a surrogate marker for visceral fat accumulation in obese children. Obesity (Silver Spring) 2008;16:384-8.
7. Haider DG, Schindler K, Schaller G, et al. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006;91:1578-81.
8. Ersoy C, Sadikoglu G, Orhan H. Body fat distribution has no effect on serum visfatin levels in healthy female subjects. Cytokine 2010;49:275-8.
9. Revollo JR, Körner A, Mills KF, et al. Nampt/PBEF/ Visfatin regulates insulin secre-tion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 2007;6:363-75.
10. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005;307:426-30.
11. Samal B, Sun Y, Stearns G, et al. Cloning andcharacterization of the cDNA encod-ing a novel human pre–B-cell colony-enhancing factor. Molec Cell Biol 1994;14:1431-7.
12. Ognjanovic S, Bao S, Yamamoto SY, et al. Genomic organization of the gene coding for human pre–Bcell colony enhancing factor and expression in human fetal mem-branes. J Mol Endocrinol 2001;26:107-17.
13. Beltowski J. Apelin and visfatin: Unique “beneficial” adipokines upregulated in obesity? Med Sci Monit 2006;12: RA112-9.
14. Haider DG, Schaller G, Kapiotis S, et al. The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 2006;49:1909-14.
15. Zhu J, Schott M, Liu R, et al. Intensive glycemic control lowers plasma visfatin lev-els in patients with type 2 diabetes. Horm Metab Res 2008;40:801-5.
16. Zhang YY, Gottardo L, Thompson R, et al. A visfatin promoter polymorphism is associated with low-grade inflammation and type 2 diabetes. Obesity (Silver Spring) 2006;14:2119-26.
17. Bailey SD, Loredo-Osti JC, et al. Common polymorphisms in the promoter of the visfatin gene (PBEF1) influence plasma insulin levels in a FrenchCanadian popula-tion. Diabetes 2006;55:2896-902.
18. Körner A, Böttcher Y, Enigk B, et al. Effects of genetic variation in the visfatin gene (PBEF1) on obesity, glucose metabolism, and blood pressure in children. Metabo-lism 2007;56:772-7.
19. Jian WX, Luo TH, Gu YY, et al. The visfatin gene is associated with glucose and lipid metabolism in in a Chinese population. Diabet Med 2006;23:967-73.
20. Pi-Sunyer X, Blackburn G, Brancati FL, et al. Reduction in weight and cardiovascu-lar disease risk factors in individuals with type 2 diabetes: Oneyear results of the look AHEAD trial. Diabetes Care 2007;30:1374-83.
21. Ishida W, Satoh J. Characteristic of metformin for treatment of impaired glucose tolerance. Nippon Rinsho 2005;63:433-7.
22. Bagry HS, Raghavendran S, Carli F. Metabolic Syndrome and Insulin Resistance: Perioperative Considerations, Anesthesiology 2008;108:506-23.
23. Gokcel A, Gumurdulu Y, Karakose H, et al. Evaluation of the safety and efficacy of sibutramine, orlistat, and metformin in the treatment of obesity. Diabetes Obes Metab 2002;4:49-55.
24. Kay JP, Alemzadeh R, Langley G, et al. Beneficial effects of metformin in normo-glycemic morbidly obese adolescents. Metabolism 2001;50:1457-61.
25. Becker ML, Aarnoudse AJ, Newton-Cheh C, et al. Common variation in the NOS1AP gene is associated with reduced glucose-lowering effect and with in-creased mortality in users of sulfonylurea. Pharmacogenet Genomics 2008;18:591-7.
26. Sun H, Gong ZC, Yin JY, et al. The association of adiponectin allele 45T/G and -11377C/G polymorphisms with Type 2 diabetes and rosiglitazone response in Chi-nese patients. Br J Clin Pharmacol 2008;65:917-26.
27. Kang ES, Park SY, Kim HJ, et al. The influence of adiponectin gene polymerphism on the rosiglitazone response in patients with type 2 diabetes. Diabetes Care 2005;28:1139-44.
28. Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome—a new world-wide defini-tion. A Consensus Statement from the International Diabetes Federation. Diabetic Medicine 2006;23:469-80.
29. R. Hume. Prediction of lean body mass from height and weight. J Clin Path 1966;19: 389-95.
30. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52.
31. Executive summary of the third report of the National Cholesterol Education Pro-gram (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97.
32. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1998;16:1215.
33. Mirzaei K, Hossein-nezhad A, Hosseinzadeh-Attar M, et al. Relationship between genotype and serum levels of adipokines and bone mineral density in type 2 diabetes mellitus patients. Iranian Journal of Diabetes and Lipid Disorders 2009;77-86.
34. Zhang WB. The Association of Single Nucleotide Polymorphism of Visfatin Gene with Type 2 Diabetes in GanSu Han Population. China 2 January 2010.
35. Kim JH, Kim SH, Im JA, et al. The relationship between visfatin and metabolic syndrome in postmenopausal women. Maturitas 2010;67:67-71.
36. Esteghamati A, Alamdari A, Zandieh A, et al. Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity. Diabetes research and clinical practice 2011;91:154- 8.
37. de Luis DA, Sagrado MG, Aller R, et al. Circulating visfatin in obese non-diabetic patients in relation to cardiovascular risk factors, insulin resistance, and adipocyto-kines: A contradictory piece of the puzzle. Nutrition 2010;26:1130-3.
38. Zahorska-Markiewicz B, Olszanecka-Glinianowicz M, Janowska J, et al. Serum con-centration of visfatin in obese women. Metabolism Clinical and Experimental 2007;56:1131-4.
39. Jin H, Jiang B, Tang J, et al. Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol. Diabetes research and clinical practice 2008;79:412-8.
40. Mirzaei K, Hossein-nezhad A, Hosseinzadeh-Attar M, et al. Variation in the visfatin gene may alter the required dosage of Oral antidiabetic agents in type 2 diabetic pa-tients. Iranian Journal of Diabetes and Lipid Disorders 2009;87-94.

APA	SUSLEYICI B, Koldemir Gunduz M, KAYHAN F, ÇAGATAY P, TASKIN M (2021). The effect of visfatin rs2110385 gene polymorphism over oral antidiabetic drug response . , 2134 - 2139. 10.5455/annalsmedres.2021.02.129
Chicago	SUSLEYICI Belgin,Koldemir Gunduz Meliha,KAYHAN Figen Esin,ÇAGATAY PENBE,TASKIN MUSTAFA The effect of visfatin rs2110385 gene polymorphism over oral antidiabetic drug response . (2021): 2134 - 2139. 10.5455/annalsmedres.2021.02.129
MLA	SUSLEYICI Belgin,Koldemir Gunduz Meliha,KAYHAN Figen Esin,ÇAGATAY PENBE,TASKIN MUSTAFA The effect of visfatin rs2110385 gene polymorphism over oral antidiabetic drug response . , 2021, ss.2134 - 2139. 10.5455/annalsmedres.2021.02.129
AMA	SUSLEYICI B,Koldemir Gunduz M,KAYHAN F,ÇAGATAY P,TASKIN M The effect of visfatin rs2110385 gene polymorphism over oral antidiabetic drug response . . 2021; 2134 - 2139. 10.5455/annalsmedres.2021.02.129
Vancouver	SUSLEYICI B,Koldemir Gunduz M,KAYHAN F,ÇAGATAY P,TASKIN M The effect of visfatin rs2110385 gene polymorphism over oral antidiabetic drug response . . 2021; 2134 - 2139. 10.5455/annalsmedres.2021.02.129
IEEE	SUSLEYICI B,Koldemir Gunduz M,KAYHAN F,ÇAGATAY P,TASKIN M "The effect of visfatin rs2110385 gene polymorphism over oral antidiabetic drug response ." , ss.2134 - 2139, 2021. 10.5455/annalsmedres.2021.02.129
ISNAD	SUSLEYICI, Belgin vd. "The effect of visfatin rs2110385 gene polymorphism over oral antidiabetic drug response ". (2021), 2134-2139. https://doi.org/10.5455/annalsmedres.2021.02.129

APA	SUSLEYICI B, Koldemir Gunduz M, KAYHAN F, ÇAGATAY P, TASKIN M (2021). The effect of visfatin rs2110385 gene polymorphism over oral antidiabetic drug response . Annals of Medical Research, 28(12), 2134 - 2139. 10.5455/annalsmedres.2021.02.129
Chicago	SUSLEYICI Belgin,Koldemir Gunduz Meliha,KAYHAN Figen Esin,ÇAGATAY PENBE,TASKIN MUSTAFA The effect of visfatin rs2110385 gene polymorphism over oral antidiabetic drug response . Annals of Medical Research 28, no.12 (2021): 2134 - 2139. 10.5455/annalsmedres.2021.02.129
MLA	SUSLEYICI Belgin,Koldemir Gunduz Meliha,KAYHAN Figen Esin,ÇAGATAY PENBE,TASKIN MUSTAFA The effect of visfatin rs2110385 gene polymorphism over oral antidiabetic drug response . Annals of Medical Research, vol.28, no.12, 2021, ss.2134 - 2139. 10.5455/annalsmedres.2021.02.129
AMA	SUSLEYICI B,Koldemir Gunduz M,KAYHAN F,ÇAGATAY P,TASKIN M The effect of visfatin rs2110385 gene polymorphism over oral antidiabetic drug response . Annals of Medical Research. 2021; 28(12): 2134 - 2139. 10.5455/annalsmedres.2021.02.129
Vancouver	SUSLEYICI B,Koldemir Gunduz M,KAYHAN F,ÇAGATAY P,TASKIN M The effect of visfatin rs2110385 gene polymorphism over oral antidiabetic drug response . Annals of Medical Research. 2021; 28(12): 2134 - 2139. 10.5455/annalsmedres.2021.02.129
IEEE	SUSLEYICI B,Koldemir Gunduz M,KAYHAN F,ÇAGATAY P,TASKIN M "The effect of visfatin rs2110385 gene polymorphism over oral antidiabetic drug response ." Annals of Medical Research, 28, ss.2134 - 2139, 2021. 10.5455/annalsmedres.2021.02.129
ISNAD	SUSLEYICI, Belgin vd. "The effect of visfatin rs2110385 gene polymorphism over oral antidiabetic drug response ". Annals of Medical Research 28/12 (2021), 2134-2139. https://doi.org/10.5455/annalsmedres.2021.02.129